Q: Could you summarize the key efficacy findings from the final EMBARK data, particularly regarding overall survival, and how these results compare with earlier endpoints such as metastasis-free survival?
Stephen Freedland, MD: Yeah. So the…
Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer
